INS and type 2 diabetes mellitus: The ReFLeCT study demonstrated that switching to degludec from other basal insulins was associated with significant reductions in the rates of overall, nonsevere, nocturnal, severe or BG-confirmed, and severe or BG-confirmed symptomatic hypoglycemia, and improved glycemic control and treatment satisfaction in patients with T1D or T2D.